SRR2932815
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.430
- MYOGENESIS+0.390
- UV_RESPONSE_DN+0.340
- COAGULATION+0.330
- INFLAMMATORY_RESPONSE+0.300
- NOTCH_SIGNALING+0.300
- TGF_BETA_SIGNALING+0.300
- PANCREAS_BETA_CELLS+0.290
- KRAS_SIGNALING_UP+0.270
Top 10 suppressed
- P53_PATHWAY-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
- CHOLESTEROL_HOMEOSTASIS-0.230
- ESTROGEN_RESPONSE_LATE-0.210
- DNA_REPAIR-0.190
- FATTY_ACID_METABOLISM-0.180
- E2F_TARGETS-0.170
- GLYCOLYSIS-0.150
- MYC_TARGETS_V2-0.140
- OXIDATIVE_PHOSPHORYLATION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CQ-6224-01A-11R-1915-07 | — | — | 0.876 |
| 2 | TCGA-CV-7435-01A-11R-2132-07 | — | — | 0.832 |
| 3 | TCGA-CR-7382-01A-11R-2132-07 | — | — | 0.816 |
| 4 | SRR29022840 | — | A | 0.804 |
| 5 | TCGA-44-6774-01A-21R-1858-07 | — | cohortA1 | 0.799 |
| 6 | TCGA-CR-7377-01A-11R-2016-07 | — | — | 0.794 |
| 7 | SRR6013569 | — | cohortMD2 | 0.792 |
| 8 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.783 |
| 9 | cdb7b56c-ddca-4596-bfa2-6823c12837e2 | — | — | 0.777 |
| 10 | TCGA-XF-AAN4-01A-11R-A42T-07 | — | — | 0.776 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |